SCHEMBL23748209

SCHEMBL23748209

C=CCOc1ccc(Cl)cc1C(O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.53
TSHR P16473 2/20 0.53
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.39
SCN4A P35499 1/20 0.39
PTGDR Q13258 1/20 0.39
CYP2D6 P10635 2/20 0.39
SLC22A1 O15245 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
HTR1A P08908 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
GCGR P47871 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748137 0.89 GAA (0.50) GAATSHRNPC1RAB9APTGDR2
SCHEMBL23748311 0.85 GAA (0.51) GAATSHRNPC1RAB9APTGDR2
SCHEMBL23748186 0.84 MAPT (0.44) GAATSHRCYP2D6SLC22A1LMNA
SCHEMBL23748235 0.83 DRD2 (0.52) GAATSHRCYP2D6SLC22A1LMNA
SCHEMBL23748225 0.81 ADRB2 (0.39) GAATSHRCYP2D6SLC22A1LMNA
SCHEMBL10712718 0.77 CNR2 (0.56) TSHRPTGDR2SCN4ACYP2D6LMNA
SCHEMBL13777319 0.77 GAA (0.54) GAATSHRNPC1RAB9APTGDR2
SCHEMBL24353648 0.77 TSHR (0.48) GAATSHRNPC1RAB9APTGDR2
SCHEMBL23748141 0.77 TSHR (0.48) GAATSHRNPC1RAB9APTGDR2
SCHEMBL24834940 0.76 SMN1; SMN2 (0.43) GAATSHRCYP2D6SLC22A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 GAA 225/4885TSHR 2251/4885NPC1 2285/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP GAA 200/4885TSHR 2179/4885NPC1 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.